CLRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Cellectar Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.12−0.02 (-1.75%)
Close on Oct 19, 2026
- Market cap
- $13.70M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -81.4% | -47.3% | -190.9% | |
| Return on assets | -53.9% | -42.6% | -107.7% | |
| Current ratio | 7.47 | 16.26 | 2.96 | |
| Diluted shares | 0M | 0M | 3M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Cellectar Biosciences generated $150.87M from operations and spent $1.34M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$150.87M
Used
$1.34M
Capital expenditure$1.34M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$21.79M
- Cash generatingOperating cash flow above zero-$23.12M
- Return on assets improvedROA up on the prior year-369.2% → -85.5%
- Earnings backed by cashOperating cash flow above net income-$23.12M vs -$21.79M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.58 → 2.96
- No dilutionShare count did not rise1M → 3M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –